Table 1 Patient characteristics.

From: Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party

 

Numbers of patients (%)

Total, N = 72

Median age at HCT [years] (range)

58 (36–73)

  Patients older than 60 years

27 (38)

  Female

21 (29)

  Male

51 (71)

Karnofsky index at HCT

  100%

29 (44)

  90%

22 (33)

  80%

14 (21)

  70%

1 (2)

Median HCT-CI (range)a

0 (0–6)

  Patients with HCT-CI ≥3

8 (11)

Cytogenetic abnormalities

  TP53del/mut

29 (40)

  Deletion(11q)/no TP53del/mut

7 (10)

  Other/no del(11q), no TP53del/mut

13 (18)

  None

23 (32)

Previous lines of therapies, median (range)

3 (1–8)

Idelalisib

  Median duration in months (range)

6 (1–28)

  Idelalisib as last line prior to HCT

48 (67)

  Idelalisib during course of CLL but not as last line

24 (33)

Drug exposure for CLL treatment, N of patients

  Chemotherapy naive

20 (28)

  Purine analogue therapy

41 (57)

  Ibrutinib

31 (43)

  Venetoclax

13 (18)

  Alemtuzumab

10 (14)

Chemoimmunotherapy sensitivity

  Not exposed

19 (26)

  Sensitive disease

33 (45)

  Poorly responsive/refractoryb

20 (27)

Failure of at least one pathway inhibitor

46 (64)

Status at HCT

  Complete remission

5 (7)

  Partial remission

54 (77)

  Stable or progressive disease

11 (15)

Donor type

  HLA-identical sibling

21 (29)

  Other (partially) matched related donor

10 (14)

  8/8 HLA-compatible unrelated donor (UD)

25 (35)

  HLA-compatible UD, HLA data missing

12 (17)

  Partially matched UD

4 (6)

CMV constellation

  Donor and recipient CMV neg.

19 (27)

  Donor or recipient CMV pos.

52 (73)

Sex constellation

  Female patient–female donor

10 (14)

  Female patient–male donor

11 (16)

  Male patient–female donor

14 (20)

  Male patient–male donor

35 (50)

Conditioning regimen

  Non-myeloablative based on 2 Gray TBI

11 (15)

  Reduced intensity

47 (65)

  High-dose therapy

14 (19)

Stem cell source

  Peripheral blood stem cells

67 (93)

  Bone marrow

4 (6)

  Cord blood

1 (1)

GVHD prophylaxis

  CSA with/without MTX/MMF

62 (86)

  Tacrolimus with/without MTX/MMF

8 (11)

  Other

2 (3)

  ATG

39 (54)

  PTCY

9 (13)

  Alemtuzumab

9 (13)

  1. N number, HCT hematopoietic cell transplantation, HCT-CI hematopoietic cell transplantation—comorbidity index, CMV cytomegalovirus, GVHD graft-versus-host disease, TBI total body irradiation, CSA cyclosporine A, MTX methotrexate, MMF mycophenolate mofetil, PBSC peripheral blood stem cells, ATG anti-thymocyte globulin, PTCY posttransplant cyclophosphamide.
  2. aInformation on the HCT-CI was not available for 22 patients.
  3. bNo response or re-treatment within 24 months.
Back to article page